With some notable company building projects under its belt with the likes of platform plays Addex Pharmaceuticals Ltd., Genmab A/S and Molecular Partners AG, Index Ventures now has proof of principle for the other side of its two-headed investment strategy.
Last month, one of its "asset-centric" investments, PanGenetics B.V., sold a Phase I antibody against nerve growth factor to Abbott Laboratories for $170 million up front and the potential of another $20 million in milestones (see BioCentury, Nov. 16).
Index is one of the most active backers of early stage biotechs, having invested in 15 series A and B rounds in the past four years. Of these, five are platforms being built out into companies. The other 10 are asset-centric entities that contain one asset, or a handful at